STTR Phase II: Development of a Lead Optimization Chip for Drug Discovery

该奖项是根据2009年《美国复苏和再投资法案》(Public Law 111-5)资助的。这个小型企业技术转让(STTR)第二阶段项目将致力于进一步开发和商业化一种多酶铅优化芯片(多酶芯片)，用于高通量地产生铅化合物类似物，并结合基于细胞的筛选来快速鉴定生物活性衍生物。这种能力直接影响到药物发现中的一个关键瓶颈，即有效地优化先导化合物以开发具有最佳药理特性的药物。Solidus Biosciences，Inc.建议将六种生物催化与药理筛选相结合，以提供针对细胞特定靶标的生物活性化合物的快速鉴定，这是一种新的先导优化范式。此外，Multisyme芯片平台将非常适合于相关行业的领先优化，包括农用化学品、化妆品和化妆品。因此，Solidus技术将提高制药、化妆品和化工行业的竞争力和效率，并将成为新的和改进的商业产品的丰富来源。这项研究的更广泛影响是Solidus生物科学公司将在生产更好、更安全的药物、降低这些药物的开发成本和提高制药行业的整体效率方面取得进展。SoliDus将生产供制药和生物技术公司购买的Multisyme芯片，以促进他们的铅优化计划，特别是那些涉及天然产品衍生和复杂合成小分子铅的计划。在第二阶段开发的低温保存技术将使第一阶段生产的芯片和芯片处理设备得以销售，并将使Solidus技术平台无缝渗透到该公司的目标市场。

This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).This Small Business Technology Transfer (STTR) Phase II project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products.The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets.